HomeCompareAVCTF vs GBDC

AVCTF vs GBDC: Dividend Comparison 2026

AVCTF yields 230.65% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 AVCTF wins by $258.37M in total portfolio value
10 years
AVCTF
AVCTF
● Live price
230.65%
Share price
$0.87
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$279.22M
Annual income
$150,694,330.53
Full AVCTF calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — AVCTF vs GBDC

📍 AVCTF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodAVCTFGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, AVCTF + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
AVCTF pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

AVCTF
Annual income on $10K today (after 15% tax)
$19,605.58/yr
After 10yr DRIP, annual income (after tax)
$128,090,180.95/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, AVCTF beats the other by $114,107,057.20/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of AVCTF + GBDC for your $10,000?

AVCTF: 50%GBDC: 50%
100% GBDC50/50100% AVCTF
Portfolio after 10yr
$150.03M
Annual income
$83,572,532.18/yr
Blended yield
55.70%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

AVCTF
No analyst data
Altman Z
-7.0
Piotroski
3/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

AVCTF buys
0
GBDC buys
0
No recent congressional trades found for AVCTF or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricAVCTFGBDC
Forward yield230.65%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$279.22M$20.85M
Annual income after 10y$150,694,330.53$16,450,733.83
Total dividends collected$265.09M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC

Year-by-year: AVCTF vs GBDC ($10,000, DRIP)

YearAVCTF PortfolioAVCTF Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$33,765$23,065.39$12,492$1,791.70+$21.3KAVCTF
2$108,915$72,786.16$16,527$3,160.58+$92.4KAVCTF
3$335,962$219,422.65$23,588$5,904.90+$312.4KAVCTF
4$992,036$632,556.65$37,141$11,901.65+$954.9KAVCTF
5$2,807,112$1,745,633.43$66,205$26,463.38+$2.74MAVCTF
6$7,619,990$4,616,380.77$137,452$66,612.65+$7.48MAVCTF
7$19,864,891$11,711,501.13$342,372$195,298.53+$19.52MAVCTF
8$49,789,295$28,533,861.41$1,053,292$686,954.33+$48.74MAVCTF
9$120,113,025$66,838,479.41$4,111,439$2,984,416.95+$116.00MAVCTF
10$279,215,267$150,694,330.53$20,849,974$16,450,733.83+$258.37MAVCTF

AVCTF vs GBDC: Complete Analysis 2026

AVCTFStock

Avacta Group Plc, a clinical stage biopharmaceutical company, develops cancer therapies and diagnostics based on its proprietary Affimer and pre|CISION platforms in the United Kingdom, North America, South Korea, and rest of Asia and Europe. It operates through Diagnostics and Therapeutics segments. The company develops custom Affimer proteins for customer products and in-house diagnostic assays. It also develops AffiDX SARS-CoV-2 lateral flow rapid antigen tests, as well as Affimer reagents for third party products; and novel cancer immunotherapies combining proprietary platforms. The company has a research collaboration with pre|CISION technology incorporates a substrate that is sensitive to cleavage by fibroblast activation protein alpha; drug development collaboration with LG Chem Life Sciences; partnership with Tufts University School of Medicine for developing Affimer drug conjugate therapies; licensing agreement with POINT Biopharma Inc. for the development of tumour activated radiopharmaceuticals; and drug development partnership with AffyXell to develop engineered mesenchymal stem cells to treat autoimmune diseases. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.

Full AVCTF Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this AVCTF vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

AVCTF vs SCHDAVCTF vs JEPIAVCTF vs OAVCTF vs KOAVCTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.